Henry Koo

Statistics

Publications

Citations

874

H-Index

Active since

2002

Affiliations

Recombinant Antibody Technology (United Kingdom)(Current)

Henry Koo is an author at Recombinant Antibody Technology (United Kingdom) specializing in molecular oncology, oncology, and therapeutic antibody development.

Publications per year

2002–2006

Publications

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Douglas Burtrum, Zhenping Zhu, Dan Lu et al. · PubMed · 2003 · 349 citations

Medicine, Oncology, Pharmacology +15

A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity

Dan Lu, Haifan Zhang, Henry Koo et al. · Journal of Biological Chemistry · 2005 · 180 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity

Z Zhu, Koichi Hattori, H Zhang et al. · Leukemia · 2003 · 157 citations

Pharmacy, Oncology, Pharmacology +17

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

Yan Wu, Zhaojing Zhong, James Huber et al. · Clinical Cancer Research · 2006 · 151 citations

Medicine, Cancer Biology, Oncology +17

Cloning, expression, and purification of mouse heparanase

Hua‐Quan Miao, Elizabeth Navarro, Sheetal Patel et al. · Protein Expression and Purification · 2002 · 37 citations

Life Sciences, Biotechnology, Molecular Biology +9

1–5 of 5